Teva Pharmaceutical Industries Ltd (TEVA) 70.98 $TEVA
United States Multiple Sclerosis Market Report 2015-2019 - RRMS, SPMS, PPMS & PRMS Breakdown
M2 - Wed Jul 29, 5:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jhg52g/multiple) has announced the addition of the "Multiple Sclerosis Market in the US 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis. Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. The US FDA has approved certain disease-modifying drugs for treating various forms of multiple sclerosis. These drugs interact with the immune system to reduce the number of relapses. Copaxone (glatiramer acetate) by Teva Pharmaceutical, Avonex (interferon beta-1a) and Tysabri (natalizumab) by Biogen, Gilenya (fingolimod) by Novartis, and Betaseron (interferon beta-1b) by Bayer are some of the disease-modifying drugs indicated for the treatment of the disease. Daclizumab by Biogen and BAF312 by Novartis are disease-modifying drugs expected to be launched during the forecast period. According to the report, in 2014, currently, medications that can produce the remission of multiple sclerosis in patients are absent. In addition, there are no established treatment procedures for multiple sclerosis. The available drugs in the market are only intended to modify the course of the disease and treat relapses. Some of the drugs are also meant for the symptomatic treatment of the patient and for managing emotional health. Thus, there is a lucrative space for companies that can address the issue of unmet medical needs in the market and develop drugs that can completely cure the disease. Further, the report states that unknown disease etiology has made it difficult for researchers to develop drugs that can target its cause. Multiple sclerosis can be broadly classified into four types: - RRMS - SPMS - PPMS - PRMS On the basis of route of administration of the drugs, the market is grouped into the following categories: - Oral - Parenteral On the basis of type of molecule of the drugs, the market is grouped into the following categories: - Small Molecules - Biologics Key Vendors - Bayer AG - Biogen - Merck Serono - Novartis AG - Teva Pharmaceutical Industries Ltd. Other Prominent Vendors - AB Science - Abbvie - Acorda Therapeutics - Active Biotech - Artielle - Astellas - AstraZeneca - Canbex - F. Hoffmann-La Roche - GeNeuro - GlaxoSmithKline - Glenmark - InnoBioscience Pharmaceuticals - Ipsen - Mapi-Pharma - medDay Pharmaceuticals - MediciNova - Mitsubishi Tanabe - Opexa Therapeutics - Osmotica - Pfizer - Receptos - RedHill Biopharma - Sanofi - Trophos - XenoPort For more information visit http://www.researchandmarkets.com/research/jhg52g/multiple
OPXA: 0.43 (+0.02), RDHL: 14.92 (-0.49), MRK: 58.81 (+1.29), TEVA: 70.98 (-0.43), GSK: 42.83 (+1.12), ACOR: 33.72 (-0.89), NVS: 103.85 (+1.06)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 123.42 (-0.45), AGN: 337.28 (-2.22), GILD: 116.40 (+3.33), JAZZ: 189.65 (-3.37), TEVA: 70.98 (-0.43), SNY: 53.78 (-0.03), REGN: 543.77 (-8.68)
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:13PM CDT
Allergan (AGN) has agreed to divest global generic pharmaceuticals business to Teva (TEVA) for $40.5 billion.
AGN: 337.28 (-2.22), MYL: 56.79 (+0.44), TEVA: 70.98 (-0.43), AMAG: 64.87 (-1.36)
SuperValu and Pfizer are big market movers
AP - Tue Jul 28, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
RAI: 83.79 (-0.41), QSR.TO: 55.47 (+0.12), RJET: 5.14 (+1.70), SVU: 8.70 (+0.56), PFE: 35.72 (+0.37), IR: 61.71 (+1.01), MYL: 56.79 (+0.44), BECN: 35.83 (+2.24), MAS: 26.09 (+0.46), PGNX: 8.83 (-0.59), QSR: 43.00 (+0.25), TEVA: 70.98 (-0.43), WAB: 100.90 (+1.28), IPGP: 91.92 (+2.21)
Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up
at Investor's Business Daily - Tue Jul 28, 3:03PM CDT
Cataplexy -- sudden temporary muscle weakness -- is one of the most devastating symptoms of narcolepsy, a neurological disorder that disrupts sleep and wake cycles. Victims are prone to fall asleep suddenly in the middle of the day -- while driving,...
JNJ: 100.02 (+1.00), JAZZ: 189.65 (-3.37), TEVA: 70.98 (-0.43), CNCE: 16.50 (-0.55)
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:00PM CDT
Exelixis (EXEL) has a Zacks Rank #2 with an earnings ESP of -9.52% and is expected to report second-quarter 2015 results on Jul 30.
MNK: 123.42 (-0.45), PRGO: 192.76 (+0.69), TEVA: 70.98 (-0.43), EXEL: 5.64 (+0.23)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 337.28 (-2.22), BIIB: 310.14 (-9.79), SHPG: 266.00 (+2.75), MYL: 56.79 (+0.44), AMGN: 170.32 (-2.42), ABBV: 71.45 (+0.22), TEVA: 70.98 (-0.43)
Fitch: Teva Remains on Watch Negative on Allergan Generics Acquisition
Business Wire - Tue Jul 28, 1:31PM CDT
According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion.
AGN: 337.28 (-2.22), TEVA: 70.98 (-0.43)
Stocks In Rebound Mode; Icon, Cadence Break Out
at Investor's Business Daily - Tue Jul 28, 12:36PM CDT
Stocks stepped up rebound efforts and hit fresh session highs Tuesday afternoon. The major averages have recouped more than half of Monday's steep losses amid more earnings reports and mixed economic data. The S&P 500 led the pack with a 1% gain. On...
AGN: 337.28 (-2.22), BIDU: 168.41 (+0.38), MYL: 56.79 (+0.44), CDNS: 20.97 (+0.18), TEVA: 70.98 (-0.43), ICLR: 77.01 (+1.81)
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Jul 28, 9:50AM CDT
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 180.74 (-1.45), AGN: 337.28 (-2.22), PPH: 74.21 (+0.27), EIS: 55.33 (-0.13), ISRA: 33.91 (-0.06), TEVA: 70.98 (-0.43)
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
at The Street - Tue Jul 28, 9:46AM CDT
Jordan's Hikma Pharmceuticals is set to become the sixth-largest U.S. generic drug maker after an agreement to buy Boehringer Ingelheim's Columbus, Ohio-based Roxane Laboratories for about $2.65 billion.
AGN: 337.28 (-2.22), MYL: 56.79 (+0.44), TEVA: 70.98 (-0.43)
Teva Pharmaceutical Industries Up 15.4% Since SmarTrend Uptrend Call (TEVA)
Comtex SmarTrend(R) - Tue Jul 28, 9:43AM CDT
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on July 9th, 2015 at $62.20. In approximately 3 weeks, Teva Pharmaceutical Industries has returned 15.42% as of today's recent price of $71.79.
TEVA: 70.98 (-0.43)
Will Teva Pharmaceutical (TEVA) Stock Rise Following BMO Capital Upgrade?
at The Street - Tue Jul 28, 9:39AM CDT
Teva Pharmaceutical (TEVA) had its rating increased to 'outperform' from 'market perform' at BMO Capital Markets this morning.
TEVA: 70.98 (-0.43)
Critical Alerts For ConocoPhillips, Teva, Pfizer Inc., Twitter and Invensense Released By InvestorsObserver
PR Newswire - Tue Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for COP, TEVA, PFE, TWTR and INVN.
PFE: 35.72 (+0.37), INVN: 12.56 (-0.85), COP: 52.82 (+0.58), TEVA: 70.98 (-0.43), TWTR: 31.61 (-4.93)
Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 310.14 (-9.79), TEVA: 70.98 (-0.43)
Teva Announces European Medicines Agency (EMA) Confirms Successful Validation of Reslizumab Marketing Authorization Application
Business Wire - Tue Jul 28, 7:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.
TEVA: 70.98 (-0.43)
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:00AM CDT
Heavier-than-normal volume put these health care and industrial ETFs in focus.
AGN: 337.28 (-2.22), SPY: 210.34 (+1.01), IYH: 162.18 (+0.08), QQQ: 111.40 (+0.27), DIA: 177.13 (+1.02), TEVA: 70.98 (-0.43), VIS: 104.39 (+1.12)
Business Highlights
By The Associated Press - AP - Mon Jul 27, 5:12PM CDT
___
AGN: 337.28 (-2.22), QSR: 43.00 (+0.25), F: 15.08 (+0.25), QSR.TO: 55.47 (+0.12), MYL: 56.79 (+0.44), TEVA: 70.98 (-0.43), MHFI: 100.36 (+1.96)
United States Multiple Sclerosis Market Report 2015-2019 - RRMS, SPMS, PPMS & PRMS Breakdown
M2 - Wed Jul 29, 5:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jhg52g/multiple) has announced the addition of the "Multiple Sclerosis Market in the US 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the multiple sclerosis market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of multiple sclerosis. Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the CNS and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in the communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with severe form of the disease can experience speech and movement problems. The US FDA has approved certain disease-modifying drugs for treating various forms of multiple sclerosis. These drugs interact with the immune system to reduce the number of relapses. Copaxone (glatiramer acetate) by Teva Pharmaceutical, Avonex (interferon beta-1a) and Tysabri (natalizumab) by Biogen, Gilenya (fingolimod) by Novartis, and Betaseron (interferon beta-1b) by Bayer are some of the disease-modifying drugs indicated for the treatment of the disease. Daclizumab by Biogen and BAF312 by Novartis are disease-modifying drugs expected to be launched during the forecast period. According to the report, in 2014, currently, medications that can produce the remission of multiple sclerosis in patients are absent. In addition, there are no established treatment procedures for multiple sclerosis. The available drugs in the market are only intended to modify the course of the disease and treat relapses. Some of the drugs are also meant for the symptomatic treatment of the patient and for managing emotional health. Thus, there is a lucrative space for companies that can address the issue of unmet medical needs in the market and develop drugs that can completely cure the disease. Further, the report states that unknown disease etiology has made it difficult for researchers to develop drugs that can target its cause. Multiple sclerosis can be broadly classified into four types: - RRMS - SPMS - PPMS - PRMS On the basis of route of administration of the drugs, the market is grouped into the following categories: - Oral - Parenteral On the basis of type of molecule of the drugs, the market is grouped into the following categories: - Small Molecules - Biologics Key Vendors - Bayer AG - Biogen - Merck Serono - Novartis AG - Teva Pharmaceutical Industries Ltd. Other Prominent Vendors - AB Science - Abbvie - Acorda Therapeutics - Active Biotech - Artielle - Astellas - AstraZeneca - Canbex - F. Hoffmann-La Roche - GeNeuro - GlaxoSmithKline - Glenmark - InnoBioscience Pharmaceuticals - Ipsen - Mapi-Pharma - medDay Pharmaceuticals - MediciNova - Mitsubishi Tanabe - Opexa Therapeutics - Osmotica - Pfizer - Receptos - RedHill Biopharma - Sanofi - Trophos - XenoPort For more information visit http://www.researchandmarkets.com/research/jhg52g/multiple
OPXA: 0.43 (+0.02), RDHL: 14.92 (-0.49), MRK: 58.81 (+1.29), TEVA: 70.98 (-0.43), GSK: 42.83 (+1.12), ACOR: 33.72 (-0.89), NVS: 103.85 (+1.06)
5 Hot Drug Stocks Top IBD's Big Cap Leaders Screen
at Investor's Business Daily - Tue Jul 28, 7:07PM CDT
Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they're proving their...
MNK: 123.42 (-0.45), AGN: 337.28 (-2.22), GILD: 116.40 (+3.33), JAZZ: 189.65 (-3.37), TEVA: 70.98 (-0.43), SNY: 53.78 (-0.03), REGN: 543.77 (-8.68)
Teva to Buy Allergan's Generics Business for $40.5B - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:13PM CDT
Allergan (AGN) has agreed to divest global generic pharmaceuticals business to Teva (TEVA) for $40.5 billion.
AGN: 337.28 (-2.22), MYL: 56.79 (+0.44), TEVA: 70.98 (-0.43), AMAG: 64.87 (-1.36)
SuperValu and Pfizer are big market movers
AP - Tue Jul 28, 3:32PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
RAI: 83.79 (-0.41), QSR.TO: 55.47 (+0.12), RJET: 5.14 (+1.70), SVU: 8.70 (+0.56), PFE: 35.72 (+0.37), IR: 61.71 (+1.01), MYL: 56.79 (+0.44), BECN: 35.83 (+2.24), MAS: 26.09 (+0.46), PGNX: 8.83 (-0.59), QSR: 43.00 (+0.25), TEVA: 70.98 (-0.43), WAB: 100.90 (+1.28), IPGP: 91.92 (+2.21)
Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up
at Investor's Business Daily - Tue Jul 28, 3:03PM CDT
Cataplexy -- sudden temporary muscle weakness -- is one of the most devastating symptoms of narcolepsy, a neurological disorder that disrupts sleep and wake cycles. Victims are prone to fall asleep suddenly in the middle of the day -- while driving,...
JNJ: 100.02 (+1.00), JAZZ: 189.65 (-3.37), TEVA: 70.98 (-0.43), CNCE: 16.50 (-0.55)
What to Expect from Exelixis (EXEL) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 2:00PM CDT
Exelixis (EXEL) has a Zacks Rank #2 with an earnings ESP of -9.52% and is expected to report second-quarter 2015 results on Jul 30.
MNK: 123.42 (-0.45), PRGO: 192.76 (+0.69), TEVA: 70.98 (-0.43), EXEL: 5.64 (+0.23)
Amgen Stock Clears Buy Point Ahead Of Earnings
at Investor's Business Daily - Tue Jul 28, 1:33PM CDT
A day after Teva Pharmaceuticals (TEVA) broke out of a base, fellow drugmaker Amgen (AMGN) is clearing a buy point. Amgen reports second quarter results after the close on Thursday. Earnings are projected to rise 3%, a slowdown from the first...
AGN: 337.28 (-2.22), BIIB: 310.14 (-9.79), SHPG: 266.00 (+2.75), MYL: 56.79 (+0.44), AMGN: 170.32 (-2.42), ABBV: 71.45 (+0.22), TEVA: 70.98 (-0.43)
Fitch: Teva Remains on Watch Negative on Allergan Generics Acquisition
Business Wire - Tue Jul 28, 1:31PM CDT
According to Fitch Ratings, the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, remain on Rating Watch Negative, following its announcement that it will acquire the global generics business of Allergan plc (Allergan; NYSE: AGN) for $40.5 billion.
AGN: 337.28 (-2.22), TEVA: 70.98 (-0.43)
Stocks In Rebound Mode; Icon, Cadence Break Out
at Investor's Business Daily - Tue Jul 28, 12:36PM CDT
Stocks stepped up rebound efforts and hit fresh session highs Tuesday afternoon. The major averages have recouped more than half of Monday's steep losses amid more earnings reports and mixed economic data. The S&P 500 led the pack with a 1% gain. On...
AGN: 337.28 (-2.22), BIDU: 168.41 (+0.38), MYL: 56.79 (+0.44), CDNS: 20.97 (+0.18), TEVA: 70.98 (-0.43), ICLR: 77.01 (+1.81)
Israel ETFs Surge on Teva Megamerger Deal - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Tue Jul 28, 9:50AM CDT
The takeover deal of Allergan by Teva has led to a surge in Israel ETFs.
IHE: 180.74 (-1.45), AGN: 337.28 (-2.22), PPH: 74.21 (+0.27), EIS: 55.33 (-0.13), ISRA: 33.91 (-0.06), TEVA: 70.98 (-0.43)
Hikma Pharmaceuticals to Buy Generic Drug Maker Roxane for $2.65 Billion
at The Street - Tue Jul 28, 9:46AM CDT
Jordan's Hikma Pharmceuticals is set to become the sixth-largest U.S. generic drug maker after an agreement to buy Boehringer Ingelheim's Columbus, Ohio-based Roxane Laboratories for about $2.65 billion.
AGN: 337.28 (-2.22), MYL: 56.79 (+0.44), TEVA: 70.98 (-0.43)
Teva Pharmaceutical Industries Up 15.4% Since SmarTrend Uptrend Call (TEVA)
Comtex SmarTrend(R) - Tue Jul 28, 9:43AM CDT
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on July 9th, 2015 at $62.20. In approximately 3 weeks, Teva Pharmaceutical Industries has returned 15.42% as of today's recent price of $71.79.
TEVA: 70.98 (-0.43)
Will Teva Pharmaceutical (TEVA) Stock Rise Following BMO Capital Upgrade?
at The Street - Tue Jul 28, 9:39AM CDT
Teva Pharmaceutical (TEVA) had its rating increased to 'outperform' from 'market perform' at BMO Capital Markets this morning.
TEVA: 70.98 (-0.43)
Critical Alerts For ConocoPhillips, Teva, Pfizer Inc., Twitter and Invensense Released By InvestorsObserver
PR Newswire - Tue Jul 28, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for COP, TEVA, PFE, TWTR and INVN.
PFE: 35.72 (+0.37), INVN: 12.56 (-0.85), COP: 52.82 (+0.58), TEVA: 70.98 (-0.43), TWTR: 31.61 (-4.93)
Watching Twitter for Moves at Teva and Biogen
at The Street - Tue Jul 28, 7:28AM CDT
Twitter sentiment predicts the big moves in two healthcare stocks-NYMX and BIIB.
BIIB: 310.14 (-9.79), TEVA: 70.98 (-0.43)
Teva Announces European Medicines Agency (EMA) Confirms Successful Validation of Reslizumab Marketing Authorization Application
Business Wire - Tue Jul 28, 7:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that it has successfully filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for reslizumab. Reslizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of inadequately controlled asthma in adult patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.
TEVA: 70.98 (-0.43)
Health Care & Industrials: Two ETFs Trading with Outsized Volume - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Jul 28, 5:00AM CDT
Heavier-than-normal volume put these health care and industrial ETFs in focus.
AGN: 337.28 (-2.22), SPY: 210.34 (+1.01), IYH: 162.18 (+0.08), QQQ: 111.40 (+0.27), DIA: 177.13 (+1.02), TEVA: 70.98 (-0.43), VIS: 104.39 (+1.12)
Business Highlights
By The Associated Press - AP - Mon Jul 27, 5:12PM CDT
___
AGN: 337.28 (-2.22), QSR: 43.00 (+0.25), F: 15.08 (+0.25), QSR.TO: 55.47 (+0.12), MYL: 56.79 (+0.44), TEVA: 70.98 (-0.43), MHFI: 100.36 (+1.96)
